{
    "clinical_study": {
        "@rank": "134656", 
        "acronym": "MEL60", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental", 
                "description": "Peptide Vaccine (LPV7) + Tetanus peptide + IFA administered in one skin location rotated to different sites on an extremity clinically uninvolved with melanoma.\nVaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Experimental", 
                "description": "Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC vaccine administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.\nVaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
            }, 
            {
                "arm_group_label": "Arm C", 
                "arm_group_type": "Experimental", 
                "description": "Peptide Vaccine (LPV7) + Tetanus peptide vaccine administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.\nResiquimod will be applied to the vaccine site immediately after the vaccine administration.\nVaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
            }, 
            {
                "arm_group_label": "Arm D", 
                "arm_group_type": "Experimental", 
                "description": "Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.\nResiquimod will be applied to the vaccine site immediately after vaccine administration.\nVaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
            }, 
            {
                "arm_group_label": "Arm E", 
                "arm_group_type": "Experimental", 
                "description": "Peptide Vaccine (LPV7) + Tetanus peptide + IFA + PolyICLC vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.\nVaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
            }, 
            {
                "arm_group_label": "Arm F", 
                "arm_group_type": "Experimental", 
                "description": "Peptide Vaccine (LPV7) + Tetanus peptide + IFA vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.\nResiquimod will be applied to the vaccine site immediately after vaccine administration.\nVaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
            }, 
            {
                "arm_group_label": "Arm G", 
                "arm_group_type": "Experimental", 
                "description": "Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC + IFA vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.\nResiquimod will be applied to the vaccine site immediately after vaccine administration.\nVaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to learn what effects (good and bad) an experimental vaccine\n      (LPV7) plus tetanus peptide and other substances called polyICLC, resiquimod, and Montanide\n      ISA-51 have on you and your melanoma.  We will also look at whether the experimental vaccine\n      and these drugs cause any changes in your immune system."
        }, 
        "brief_title": "Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists", 
        "condition": [
            "Melanoma", 
            "Metastatic Melanoma", 
            "Mucosal Melanoma"
        ], 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically proven Stage IIB - IV melanoma rendered clinically\n             free of disease by surgery, other therapy, or spontaneous remission within 6 months\n             prior to registration.\n\n               -  Patients may have had melanoma from a cutaneous, mucosal or unknown primary site\n\n               -  Patients with small radiologic or clinical findings may be eligible\n\n          -  Patients with treated brain metastases may be eligible if the following are true:\n\n               -  Total number of brain metastases ever is less than or equal to 3\n\n               -  The brain metastases have been completely removed by surgery or have been\n                  treated completely with stereotactic radiotherapy\n\n               -  There has been no evident growth of any brain metastases since treatment\n\n               -  No treated brain metastases is greater than 2 cm at the time of protocol entry\n\n          -  Patients must have at least 1 intact axillary and/or inguinal lymph node basin\n\n          -  ECOG performance status of 0-1\n\n          -  Lab parameters as follows:\n\n               -  HLA-A1, A2, A3, B35, or B51\n\n               -  ANC > 1000/mm3 and Platelets > 100,000/mm3 and Hemoglobin > 9 g/dL\n\n               -  AST and ALT up to 2.5 x ULN\n\n               -  Bilirubin up to 2.5 x ULN\n\n               -  Alkaline Phosphatase up to 2.5 x ULN\n\n               -  Creatinine up to 1.5 x ULN\n\n               -  HGBA1C level < 7%\n\n        Exclusion Criteria:\n\n          -  Patients with melanoma from a uveal or ocular primary site\n\n          -  Patients currently receiving any systemic therapy within 4 weeks of study\n             registration. Gamma knife or stereotactic radiosurgery must not be administered\n             within 1 week prior to study registration. Patients who are currently receiving\n             nitrosoureas within the preceding 6 weeks.\n\n          -  Patients who have received CTLA-4, PD-1, PD-L1, CD137, or CD27 within the prior 12\n             months.\n\n          -  Patients with known or suspected allergy to any component of the vaccine\n\n          -  HIV positive or active Hepatitis C virus\n\n          -  Patients receiving any of the following medications within 4 weeks are excluded:\n\n               -  Agents with immunomodulating activity (with the exception of non-steroidal\n                  anti-inflammatory agents and topical steroids)\n\n               -  Allergy desensitization injections\n\n               -  Systemic corticosteroids, administered parenterally or orally. Inhaled steroids\n                  (e.g. Advair, Flovent, Azmacort) are not permitted. Topical corticosteroids are\n                  acceptable including steroids with very low solubility administered nasally for\n                  local effects only (e.g. Nasonex)\n\n               -  Any growth factors (e.g. GM-CSF, G-CSF, erythropoietin).\n\n               -  Interferon therapy\n\n               -  Interleukin-2 or other interleukins\n\n          -  Other investigational drugs or investigational therapy if currently receiving or have\n             received within 1 month\n\n          -  Pregnancy or the possibility of becoming pregnant during the study. And women who are\n             breastfeeding.\n\n          -  Must not have had prior autoimmune disorders requiring cytotoxic or immunosuppressive\n             therapy, or autoimmune disorders with visceral involvement. The following are not\n             exclusionary:\n\n               -  Presence of laboratory evidence of autoimmune disease (e.g. positive ANA titer)\n                  without symptoms\n\n               -  Clinical evidence of vitiligo\n\n               -  Other forms of depigmenting illness\n\n               -  Mild arthritis requiring NSAID medications\n\n          -  Patients with a medical contradiction or potential problem with complying with the\n             protocol, in the opinion of the investigator\n\n          -  Patients with Class III or IV heart disease (according to NYHA classification)\n\n          -  Patients with a body weight < 110 lbs."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02126579", 
            "org_study_id": "15931", 
            "secondary_id": "MEL60"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B", 
                    "Arm C", 
                    "Arm D", 
                    "Arm E", 
                    "Arm F", 
                    "Arm G"
                ], 
                "description": "1.5 mL administered half intradermally and half subcutaneously.", 
                "intervention_name": "Peptide Vaccine (LPV7) + Tetanus peptide", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Arm B", 
                    "Arm D", 
                    "Arm E", 
                    "Arm G"
                ], 
                "description": "1 mL administered half intradermally and half subcutaneously", 
                "intervention_name": "PolyICLC", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Arm C", 
                    "Arm D", 
                    "Arm F", 
                    "Arm G"
                ], 
                "description": "500 mg applied to vaccine site after vaccine administration", 
                "intervention_name": "Resiquimod", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm E", 
                    "Arm F", 
                    "Arm G"
                ], 
                "description": "2 mL administered half intradermally and half subcutaneously", 
                "intervention_name": "IFA", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Poly ICLC"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "melanoma", 
            "neoplasms", 
            "Poly ICLC", 
            "Freund's Adjuvant", 
            "Metastatic melanoma", 
            "resiquimod", 
            "adjuvants", 
            "peptide vaccine"
        ], 
        "lastchanged_date": "April 30, 2014", 
        "link": {
            "description": "NCI website", 
            "url": "http://www.cancer.gov/cancertopics/types/melanoma"
        }, 
        "location": [
            {
                "contact": {
                    "email": "vmperez1@mdanderson.org", 
                    "last_name": "Vanessa Perez", 
                    "phone": "713-563-2457"
                }, 
                "contact_backup": {
                    "email": "ldhenry@mdanderson.org", 
                    "last_name": "Laura Henry", 
                    "phone": "713-792-7317"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "MDAnderson Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Sapna Patel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "eh4m@virginia.edu", 
                    "last_name": "Emily Allred", 
                    "phone": "434-982-1902"
                }, 
                "contact_backup": {
                    "email": "ks4ww@virginia.edu", 
                    "last_name": "Kristy Scott", 
                    "phone": "434-982-6714"
                }, 
                "facility": {
                    "address": {
                        "city": "Charlottesville", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22908"
                    }, 
                    "name": "University of Virginia"
                }, 
                "investigator": {
                    "last_name": "Craig Slingluff, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "7", 
        "official_title": "Open Label, Randomized, Phase I/II Study of a Long Peptide Vaccine Plus TLR Agonists for Resected Stage IIb-IV Melanoma. (MEL60)", 
        "overall_contact": {
            "email": "ks4ww@virginia.edu", 
            "last_name": "Kristy Scott, BS", 
            "phone": "434-982-6714"
        }, 
        "overall_contact_backup": {
            "email": "eh4m@virginia.edu", 
            "last_name": "Emily Allred, PhD", 
            "phone": "434-982-1902"
        }, 
        "overall_official": {
            "affiliation": "University of Virginia", 
            "last_name": "Craig Slingluff, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Safety and toxicity following vaccination with 7 long peptides in melanoma patients with and without TLR agonists.\nPatients are evaluated by safety labs and physical exams to assess for toxicity.", 
                "measure": "Number of adverse events per study arm", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "- Levels of peptide-reactive CD8+ T cells in the peripheral blood", 
                "measure": "T cell response in peripheral blood over duration of study participation", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02126579"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Virginia", 
            "investigator_full_name": "Craig L Slingluff, Jr", 
            "investigator_title": "Professor, Department of Surgery", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "CD4+ T cell responses to peptides in the vaccine, and their function", 
            "measure": "T cell response and function in peripheral blood", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "source": "University of Virginia", 
        "sponsors": {
            "collaborator": {
                "agency": "UVA Human Immune Therapy Center", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Virginia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}